Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 219,937,487 papers from all fields of science
Search
Sign In
Create Free Account
Z 321
Known as:
Z-321
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Occurrence of substance P(1-7) in the metabolism of substance P and its antinociceptive activity at the mouse spinal cord level.
C. Sakurada
,
C. Watanabe
,
T. Sakurada
Methods and Findings in Experimental and Clinical…
2004
Corpus ID: 31042566
Substance P (SP), which is known as a pain transmitter or modulator in the spinal cord, was degraded by the synaptic membranes of…
Expand
2000
2000
Decrease of sexual receptivity by prolylendopeptidase inhibitor in female rats.
I. Oosuka
,
Y. Tanaka
,
N. Miura
,
K. Yamanouchi
Japanese Journal of Pharmacology
2000
Corpus ID: 34350188
The effects of a prolylendopeptidase inhibitor, 1-[3-(2-indanylanylacetyl)-L-thioprolyl]pyrrolidine (Z-321), on lordosis behavior…
Expand
1999
1999
Pharmacokinetics and Safety of Z‐321, a Novel Specific Orally Active Prolyl Endopeptidase Inhibitor, in Healthy Male Volunteers
K. Umemura
,
K. Kondo
,
+4 authors
M. Nakashima
Journal of clinical pharmacology
1999
Corpus ID: 40633765
This study investigates the pharmacokinetics and safety profile of Z‐321, (4R)‐3‐(indan‐2‐ylacetyl)‐4‐(1‐pyrrolidinylcarbonyl)‐1…
Expand
1997
1997
Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices
N. Miura
,
S. Shibata
,
Shigenori Watanabe
Behavioural Brain Research
1997
Corpus ID: 4053512
1995
1995
Increase in the septal vasopressin content by prolyl endopeptidase inhibitors in rats
N. Miura
,
S. Shibata
,
Shigenori Watanabe
Neuroscience Letters
1995
Corpus ID: 46119928
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE